MeiraGTx Holdings (MGTX) Cash from Financing Activities (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Cash from Financing Activities of $5.3 million for Q4 2025, up 25.54% on a YoY basis from $4.2 million in Q4 2024, and up 2532.88% quarter-over-quarter from -$219000.0 in Q3 2025.
MeiraGTx Holdings (MGTX) Cash from Financing Activities (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Cash from Financing Activities for 9 years, with the latest figure at $5.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 25.54% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2025 stood at $12.3 million (down 77.5% YoY), and the FY2025 full-year result was $12.3 million, down 77.5% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $5.3 million, up from -$219000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $72.9 million in Q3 2022, with the low at -$2.6 million in Q1 2022.
- Historically, Cash from Financing Activities has averaged $13.0 million across 5 years, with a median of $1.6 million in 2024.
- The largest YoY upside for Cash from Financing Activities was 134990.74% in 2022 against a maximum downside of 1998.53% in 2022.
- MeiraGTx Holdings' Cash from Financing Activities stood at $1.3 million in 2021, then surged by 1817.61% to $24.8 million in 2022, then increased by 11.59% to $27.7 million in 2023, then slumped by 84.68% to $4.2 million in 2024, then gained by 25.54% to $5.3 million in 2025.
- The last three Cash from Financing Activities figures came in at $5.3 million (Q4 2025), -$219000.0 (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 5.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.33 Mn |
| Dec 31, 2025 | 5.33 Mn |
| Sep 30, 2025 | -219,000.00 |
| Sep 30, 2025 | -219,000.00 |
| Jun 30, 2025 | 5.45 Mn |
| Jun 30, 2025 | 5.45 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 49.96 Mn |
| Sep 30, 2024 | 49.96 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Sep 30, 2023 | -404,000.00 |
| Sep 30, 2023 | -404,000.00 |